Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 90

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 90
---
 Lipovation to reference pre-existing toxicological and pharmacological data, significantly expediting the approval process.

This formulation of candesartan, delivered via PEGylated nano-liposomes, enhances drug delivery to tumors, minimizing systemic side effects like hypotension commonly seen with free ARB administration. The use of this technology demonstrates an innovative approach to enhancing cancer therapies while repurposing existing drugs for novel clinical applications

Employees

We currently have three (3) full-time employees, three (3) part time employee, and 10 experienced consultants, including two (2) on administrative level, five(5) in the scientific and product development and three (3) in the medical (clinical trials) field. Our employees work at will and are not represented by a collective bargaining unit. We believe our relationship with our employees is excellent in most cases. We require all our employees and consultants to sign a confidentiality and non-disclosure agreement. Our success relies on our ability to hire additional employees, particularly on the local sales side. We believe there are numerous quality people to choose from throughout our area of targeted expansion.

Subsidiaries

The Company has two wholly-owned subsidiary, Revium Recovery, Ltd. and LipoVation Ltd., each organized under the laws of the State of Israel.

Legal Proceedings

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

<div align='center'>55

MANAGEMENT</div>

Executive Officers, Directors and Key Personnel

The following table sets forth information regarding our executive officers and directors:

| Name               |     | Age |     | Position                                        |
| David Akunis       |     |  59 |     | Chief Executive Officer                         |
| Inna Martin        |     |  49 |     | President, Chief Operating Officer and Director |
| Arie Gordashnikov  |     |  41 |     | Chief Financial Officer and Treasurer           |
| Daniel Bartal      |     |  59 |     | Chairman, Director                              |
| Mordechai Jacobson |     |  55 |     | Director                                        |
| Matti Munk         |     |  53 |     |